Debbie Hart, President and CEO, BioNJ

BioNJ is involved in ensuring that New Jersey retains its leading position as a center of global life sciences by facilitating the industry’s development. Since its establishment in 1994, BioNJ has grown to support some 400 members. Could you briefly outline the development of the association and its main objectives? At BioNJ, our mission is to ensure a robust life sciences ecosystem in New Jersey in which science is supported, companies are created, drugs are developed, and patients are paramount. As we say at BioNJ, patients can’t wait, and this ultimately drives everything we do....

Paying the Price: U.S. Biopharma Industry

Slashing drug prices might benefit patients in the short term, but at what cost? Catherine Howe IMAGE: GoBoldly Drug makers are “getting away with murder” said President Trump in his first press-conference as president-elect, unsettling prospects of a favorable industry partnership with a condemnation of high drug prices that laid blame on pharmaceutical companies, prompting representatives across the value chain, from manufacturers to wholesalers to payers and pharmacy benefit managers (PBMs), to shift blame to such an extent that they have run out of fingers to point. The Pharmaceutica...

Gil Roth, President, The Pharma & Biopharma Outsourcing Association (PBOA)

The PBOA effectively promotes Contract Manufacturing organizations and protects their interests. Could you give some background to the Pharma & Biopharma Outsourcing Association (PBOA), its main objectives, and how it realizes them? PBOA was established in 2014 and is dedicated to representing Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs). We have worked with the FDA to negotiate the second five-year iteration of the Generic Drug User Fee Authorization (GDUFA) and developed a new financial model that will be less burdensome f...

Dean J. Paranicas, President and CEO, HealthCare Institute of New Jersey (HINJ)

HealthCare Institute of New Jersey endeavors to ensure a favorable environment so that New Jersey remains at the center of global life science research. HINJ has acted as a voice for New Jersey’s life sciences industry for over 20 years. How has the association developed alongside the industry? Having earned the reputation as the ‘medicine chest of the world’, biopharmaceuticals is both the largest industry sector in New Jersey and one of the largest such clusters in the United States. HINJ was a response to the need to elevate awareness and advocate for a supportive environment that ...

    Pooling its force: U.S. Biopharmaceutical industry channels R&D focus amid changing tides

    In a time of uncertainty across the board, the United States is still “going boldly” ahead, bringing us innovation and constantly adapting its business model. Catherine Howe IMAGE: Mario_luengo As with other sectors across the United States, the biopharmaceutical industry has entered 2017 amidst a great deal of speculation regarding prospective changes under the new Administration. Having come under fire for high drug pricing during Donald Trump’s first news conference as President-elect, many companies took a hit on stock prices in early 2017, and pharma giants such as Johnson &am...

    Suri Chetty, Director, Business Development, Unichem

    Unichem are in partnership with Novvi to bring synthetic renewable and biodegradable hydrocarbon production to South Africa. How has Unichem developed its product portfolio over the years? We have always been involved in specialty chemicals but have changed a lot since we began in 1997. We have, however, never traded anything outside Group III and Group IV base oils – we operate in that 10% of the lube market. Everything else tends to be focused on molecules that are synthetic and progressive, which means driving energy consumption lower, reducing emissions, and extending oil life. We try ...

    Matthew Spalding, Director, Hydrocarbons & Chemicals (SE Asia), WorleyParsons

    WorleyParsons is a major ECPM player on Jurong island and is adapting its offering to cope with a faltering demand for new projects. WorleyParsons boasts a longstanding relationship with Singapore and the greater region, having entered and sustained joint ventures on the island decades ago. Can you please provide our readers with a more detailed history of the firm’s Singaporean presence? The Company, commenced operations in Singapore in the mid 1980s, as a result of a joint venture with Frasier. Given that our primary focus at the time was private infrastructure, the business was establis...

    Builders and Movers Diversify to Conquer

    As Singapore continues along its higher value added production journey and weathers the economic storm, EPCM contractors and service providers will have to continue to adapt, innovate, and vie for a smaller piece of the pie. Neha Ghanshamdas IMAGE: Courtesy of AKZONOBEL China’s 6.7% growth rate is hardly a new topic of conversation; some refer to this as the superpower’s “new normal”. What is often referred to as China’s chill, or the giant’s slower growth, has spurred a ripple effect across the region and the world. The state’s industrial overcapacity, coupled with lower dema...

    Argentina Petrochemicals and Chemicals 2016

    Country: Argentina • Industry: Chemicals • Publication: Global Business Reports • Release Date: November 2016 • Authors: Alice Pascoletti, Laura Brangwin, Harriet Bailey, Katherina Prügel and Francis Lister Executive Summary: In the wake of Argentina’s historic change in government, the discovery of huge shale oil and gas resources and the consequent focus for private investment in hydrocarbons and raw materials downstream, the country’s chemical market shows promising projections of expansion on the horizon. Since his December 2015 election, President Mauricio Macri has foc...

    More articles